NEW YORK, April 27, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against The Bancorp, Inc. (NASDAQ: TBBK) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Bancorp, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/the-bancorp-inc. Investors have until May 16, 2025, to ask the Court to be appointed to lea ...

NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Allbirds, Inc. (“Allbirds” or the “Company”) (NASDAQ: BIRD).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Allbirds and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On March 11, ...

NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  iRobot Corporation (“iRobot” or the “Company”) (NASDAQ: IRBT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether iRobot and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On March 12, ...

NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Bitfarms Ltd. (“Bitfarms” or the “Company”) (NASDAQ: BITF).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Bitfarms and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On December 9, ...

NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Endeavour Silver Corp. (“Endeavour” or the “Company”) (NYSE: EXK).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Endeavour and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On Apr ...

NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of TechTarget, Inc. (“TechTarget” or the “Company”) (NASDAQ: TTGT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether TechTarget and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On April ...

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud and unlawful business practices by Kyndryl Holdings, Inc. following allegations from Gotham City regarding manipulated financial metrics [1][3]. Group 1: Investigation Details - Pomerantz LLP is representing investors of Kyndryl and is looking into whether the company and its officers engaged in securities fraud [1]. - The investigation was prompted by a report from Gotham City, a short-seller, which accused Kyndryl of manipulating its reported adjusted EBITDA and adjusted free cash flow [3]. Group 2: Market Reaction - Following the allegations, Kyndryl's stock price dropped by $1.74, or 5.11%, closing at $32.32 per share on March 27, 2025 [3]. Group 3: Firm Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering significant damages for victims of securities fraud [4].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Agilysys, Inc. and its executives, following disappointing financial results and a significant stock price drop [1][3]. Financial Performance - On January 21, 2025, Agilysys reported third quarter revenue that was below market expectations and the company's own guidance, leading to a downward revision of its full-year 2025 revenue outlook [3]. - The CEO acknowledged underestimating sales challenges related to the point-of-sale (POS) segment and noted that the year "could have been a lot better" [3]. - Following the announcement, Agilysys's stock price fell by $25.23 per share, or 20.04%, closing at $100.67 per share on January 22, 2025 [3]. Legal Investigation - Pomerantz LLP is actively investigating claims on behalf of Agilysys investors regarding possible securities fraud or other unlawful practices by the company and its officers [1].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Pliant Therapeutics, Inc and its officers or directors [1] Company Developments - On February 7, 2025, Pliant announced a voluntary pause in enrollment and dosing for the BEACON-IPF Phase 2b trial of bexotegrast due to recommendations from the independent Data Safety Monitoring Board [3] - Following this announcement, analysts from Wells Fargo and Citi downgraded Pliant, expressing uncertainty regarding the future of bexotegrast [3] Stock Performance - Pliant's stock price experienced a significant decline, falling by $4.72 per share, or 60.59%, closing at $3.07 per share on February 10, 2025 [4]

MILWAUKEE, April 24, 2025 /PRNewswire/ -- Ademi & Fruchter LLP is investigating possible securities fraud claims against UnitedHealth (NYSE: UNH). The investigation results from inaccurate statements UnitedHealth made regarding its business operations and prospects.Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you.The investigation focuses on UnitedHealth's recent revisions ...